REVIEW LEDGER
论文复核台
集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。
| 论文 | 元数据入排 | 图像/No. at risk 复核 | 依据 |
|---|---|---|---|
| Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer.PMID 40832988 · 2025-Sep-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study.PMID 40154623 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study.PMID 40419140 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial.PMID 40447230 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial.PMID 40450503 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.PMID 40500687 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331.PMID 40515508 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting.PMID 40613875 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.PMID 40700852 · 2025-Sep | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.PMID 40775055 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.PMID 40812325 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.PMID 40907513 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial.PMID 40907518 · 2025-Sep | needs_reviewThe trial is a phase 3, randomized, drug-interventional oncology study with original results, but the primary endpoint is cumulative toxicity, not a time-to-event efficacy endpoint. No OS/PFS/DFS/EFS/RFS/TTP, Kaplan-Meier, or HR data is reported. | pending- | The trial is a phase 3, randomized, drug-interventional oncology study with original results, but the primary endpoint is cumulative toxicity, not a time-to-event efficacy endpoint. No OS/PFS/DFS/EFS/RFS/TTP, Kaplan-Meier, or HR data is reported. |
| Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.PMID 40958065 · 2025-Sep | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study.PMID 40866342 · 2025-Aug-28 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.PMID 40334072 · 2025-Aug-26 | needs_reviewThe study is an oncology, human, randomized, Phase III trial with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint. The primary endpoint is major molecular response (MMR) at week 156, a categorical response rate, not a time-to-event outcome. Therefore, it does not meet the eligibility criteria for inclusion in the KM digitization cohort. | pending- | The study is an oncology, human, randomized, Phase III trial with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint. The primary endpoint is major molecular response (MMR) at week 156, a categorical response rate, not a time-to-event outcome. Therefore, it does not meet the eligibility criteria for inclusion in the KM digitization cohort. |
| A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.PMID 40737898 · 2025-Aug-26 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.PMID 40851062 · 2025-Aug-25 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.PMID 40454634 · 2025-Aug-21 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.PMID 40454639 · 2025-Aug-21 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.PMID 40454642 · 2025-Aug-21 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.PMID 40499012 · 2025-Aug-21 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.PMID 40623279 · 2025-Aug-20 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.PMID 40783289 · 2025-Aug-09 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.PMID 40127397 · 2025-Aug-07 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.PMID 40454637 · 2025-Aug-07 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.PMID 40454645 · 2025-Aug-07 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.PMID 40769977 · 2025-Aug-06 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.PMID 40683287 · 2025-Aug-02 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.PMID 40683290 · 2025-Aug-02 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial.PMID 40067142 · 2025-Aug-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial.PMID 40531520 · 2025-Aug-01 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.PMID 39978598 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial.PMID 40328571 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.PMID 40383193 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.PMID 40383194 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.PMID 40440184 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.PMID 40448579 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.PMID 40450141 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild-Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study (NCCH1512).PMID 40503645 · 2025-Aug | needs_reviewThe abstract describes an ancillary analysis of a Phase III randomized trial, but the reported outcomes (disease control rate, acneiform rash severity) are not time-to-event efficacy endpoints. No Kaplan-Meier curves, hazard ratios, or time-to-event data (OS, PFS, etc.) are mentioned. | pending- | The abstract describes an ancillary analysis of a Phase III randomized trial, but the reported outcomes (disease control rate, acneiform rash severity) are not time-to-event efficacy endpoints. No Kaplan-Meier curves, hazard ratios, or time-to-event data (OS, PFS, etc.) are mentioned. |
| Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.PMID 40524338 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole.PMID 40549110 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial.PMID 40550238 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study.PMID 40587991 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.PMID 40592025 · 2025-Aug | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.PMID 40592026 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.PMID 40602204 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC.PMID 40654300 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.PMID 40675873 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.PMID 40680752 · 2025-Aug | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |